<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954782</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL19_0003</org_study_id>
    <secondary_id>2019-002593-31</secondary_id>
    <nct_id>NCT03954782</nct_id>
  </id_info>
  <brief_title>Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.</brief_title>
  <acronym>EPICURE</acronym>
  <official_title>Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease. A National, Randomized, Multicentre Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recognized manifestations of HHT are all due to abnormalities in vascular structure.&#xD;
      Epistaxis are spontaneous, very variable, may occur as often as several times every day, and&#xD;
      are recurrent in 90% of patients and associated with chronic and severe anemia in 2-10%. They&#xD;
      also significantly reduce quality of life.&#xD;
&#xD;
      Blood transfusions are sometimes required in 10-30% of patients. Previous studies showed that&#xD;
      antiangiogenic treatments such as anti-VEGF treatment (bevacizumab) administered&#xD;
      intravenously was efficient on epistaxis and dramatically reduced nosebleeds.&#xD;
&#xD;
      Tyrosine kinase inhibitors are anti-angiogenic molecules which are available orally and could&#xD;
      therefore overcome the difficulties encountered with bevacizumab. The investigator&#xD;
      hypothesized that nintedanib, acting by indirect inhibition of the VEGF receptor should allow&#xD;
      a reduction of epistaxis in HHT patient.&#xD;
&#xD;
      Nintedanib has been used in one HHT patient following the diagnosis of Insterstitial&#xD;
      Pulmonary Fibrosis (published case report in 2017, Kovacs et al) with encouraging results.&#xD;
&#xD;
      The aim is to evaluate efficacy of nintedanib for the treatment of epistaxis in HHT patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epistaxis duration assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy or nintedanib assessed by ESS (Epistaxis Severity Score) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
    <description>This score assess the severity of epistaxis (minimum 0 corresponds to &quot;none&quot; and maximum 10 corresponds to&quot;severe&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy or nintedanib assessed by ESS questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>This score assess the severity of epistaxis (minimum 0 corresponds to &quot;none&quot; and maximum 10 corresponds to&quot;severe&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis all over the study. Assessment on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of epistaxis assessed on epistaxis grids completed by the patients.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF36 (Short Form 36) questionnaire</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessed by SF36 questionnaire</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of red blood cell transfusions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of red blood cell transfusions</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of iron infusions</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of iron infusions</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemoglobin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin level</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ferritin level</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Telangiectasia, Hereditary Hemorrhagic</condition>
  <condition>Rendu Osler Disease</condition>
  <arm_group>
    <arm_group_label>Nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral treatment of Nintedanib 150 mg soft capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral treatment of placebo soft capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib 150 mg and 100 mg soft capsules</intervention_name>
    <description>Nintedanib 150 mg soft capsules twice daily approximately 12 hours apart (i.e. 300 mg/day) for 12 weeks. In case of adverse reaction a dose reduction at 200 mg/day (100 mg twice daily) can be prescribe.</description>
    <arm_group_label>Nintedanib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral treatment of placebo soft capsule</intervention_name>
    <description>Placebo soft capsules (identical to 150 mg and 100 mg soft capsules)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Patients who have given their free informed and signed consent&#xD;
&#xD;
          -  Patients affiliated to a social security scheme or similar&#xD;
&#xD;
          -  Patients monitored for clinically confirmed HHT and/or with molecular biology&#xD;
             confirmation&#xD;
&#xD;
          -  Patient with an Epistaxis Severity Score (ESS) &gt; 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman or woman of child bearing potential&#xD;
&#xD;
          -  Woman who are breast feeding.&#xD;
&#xD;
          -  Patient who is protected adults under the terms of the law (French Public Health&#xD;
             Code).&#xD;
&#xD;
          -  Participation in another interventional clinical trial which may interfere with the&#xD;
             proposed trial&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
          -  (AST, ALT &gt; 1,5 fold upper limit of normal (ULN) and/or Bilirubin &gt; 1,5 fold upper&#xD;
             limit of normal (ULN).&#xD;
&#xD;
          -  Severe renal impairment&#xD;
&#xD;
          -  Presence of non-treated pulmonary arteriovenous malformations accessible to a&#xD;
             treatment on CT scan within 5 years.&#xD;
&#xD;
          -  Patients with hemoptysis or hematuria within 12 weeks prior to inclusion.&#xD;
&#xD;
          -  Patients with active gastro-intestinal (GI) bleeding or GI ulcers within 12 months&#xD;
             prior to inclusion.&#xD;
&#xD;
          -  Presence of cerebral arteriovenous malformation.&#xD;
&#xD;
          -  Patients who require full-dose therapeutic anticoagulation (e.g. vitamin K antagonist&#xD;
             or heparin, dabigatran) or high dose antiplatelet therapy, , patients under&#xD;
             anticoagulation with rivaroxaban, apixaban and epixaban.&#xD;
&#xD;
          -  Patients with P-glycoprotein (P-gp) substrates/inducers/inhibitors (e.g.:&#xD;
             ketoconazole, erythromycin, cyclosporine, rifampicin, carbamazepine, phenytoin, and&#xD;
             St. John's Wort).&#xD;
&#xD;
          -  Patients with known coronary artery disease or recent history of myocardial infarction&#xD;
             (within 1 year).&#xD;
&#xD;
          -  Known inherited predisposition to thrombosis or thrombotic events( including stroke&#xD;
             and transient ischemic attack, excluded superficial venous thrombosis) within 12&#xD;
             months prior to inclusion.&#xD;
&#xD;
          -  Patients with QTc prolongation&#xD;
&#xD;
          -  Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients.&#xD;
&#xD;
          -  Patient who incompletely filled in epistaxis grids within 8 weeks prior to inclusion.&#xD;
&#xD;
          -  Patient who have received intravenous bevacizumab within 6 months prior to inclusion.&#xD;
&#xD;
          -  Patient who had surgery (including ENT (Ear, Nose and Throat Specialist) surgery)&#xD;
             within 12 weeks prior to inclusion.&#xD;
&#xD;
          -  Unhealed wound.&#xD;
&#xD;
          -  Planned major surgery within the next 3 months, including liver transplantation, major&#xD;
             abdominal or intestinal surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie DUPUIS-GIROD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie DUPUIS-GIROD, MD</last_name>
    <phone>4 27 85 65 25</phone>
    <phone_ext>+33</phone_ext>
    <email>sophie.dupuis-girod@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>C LAVIGNE</last_name>
      <email>chlavigne@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>C LAVIGNE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry CHINET</last_name>
      <email>thierry.chinet@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry CHINET</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Femme-Mère-Enfant-Centre de Référence pour la maladie de Rendu-Osler</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie DUPUIS-GIROD</last_name>
      <email>sophie.dupuis-girod@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent GROBOST</last_name>
      <email>vincent.grobost@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vincent GROBOST</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène MAILLARD</last_name>
      <email>helene.maillard@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène MAILLARD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Marseille-Hôpital la conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie SEGUIER</last_name>
      <email>julie.seguier@ap-hm.de</email>
    </contact>
    <investigator>
      <last_name>Julie SEGUIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier-Hôpital St Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie RIVIERE</last_name>
      <email>s-riviere@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Sophie RIVIERE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine PARROT</last_name>
      <email>antoine-parrot@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine PARROT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU - Hôpital J.Bernard</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte GILBERT-DUSSARDIER</last_name>
      <email>brigitte.gilbert-dussardier@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte GILBERT-DUSSARDIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes-Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mallorie KERJOUAN</last_name>
      <email>mallorie.kerjouan@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Mallorie KERJOUAN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hereditary Hemorrhagic Telangiectasia (HHT)</keyword>
  <keyword>antiangiogenic therapy</keyword>
  <keyword>Tyrosine Kinase Inhibitor</keyword>
  <keyword>Nintedanib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epistaxis</mesh_term>
    <mesh_term>Telangiectasis</mesh_term>
    <mesh_term>Telangiectasia, Hereditary Hemorrhagic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

